Clinical Trial Update: Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) [Phase 1]

View source ↗

Summary

Phase 1 safety study of AP23573 (deforolimus) in patients with advanced, refractory, or recurrent malignancies has completed, including lymphoma and multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Malignant Neoplasms
• Multiple Myeloma

Drugs mentioned

• AP23573 (deforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Tumors, Lymphoma | Phase 1 | Status: COMPLETED